Psyence Biomedical Ltd. (PBM)
NASDAQ: PBM · Real-Time Price · USD
4.210
-0.100 (-2.32%)
Aug 28, 2026, 4:00 PM EDT - Market closed

Psyence Biomedical Cash Flow Statement

Millions USD. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
-6.941.01-51.16-3.21-1.86
Depreciation & Amortization
0.0100--
Loss (Gain) on Equity Investments
0.05----
Stock-Based Compensation
0.16-0.320.220.33
Other Operating Activities
-0.2-4.3649.07-0.08-
Change in Accounts Receivable
-0.23-0.10.11-0.110.1
Change in Accounts Payable
0.01-0.36-1.041.660.03
Change in Other Net Operating Assets
-10.07-0.25-0.070
Operating Cash Flow
-8.14-3.73-2.95-1.59-1.4
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-0-0.01-0.01--
Investment in Securities
-4.5----
Other Investing Activities
-0.01-0.01---0.03
Investing Cash Flow
-4.51-0.02-0.01--0.03

Financing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
-12.5--
Total Debt Issued
-12.5--
Short-Term Debt Repaid
---0.15--
Total Debt Repaid
---0.15--
Net Debt Issued (Repaid)
-12.35--
Issuance of Common Stock
-1.74---
Other Financing Activities
13.966.41-1.17-1.63
Financing Cash Flow
13.969.152.351.17-1.63

Net Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Cash Flow
1.315.4-0.6-0.42-3.06

Free Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
-8.14-3.74-2.95-1.59-1.4
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-14.74-121.22---
Levered Free Cash Flow
-4.96-3.39-1.71-0.32-
Unlevered Free Cash Flow
-4.95-3.39-1.68-0.32-

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Change in Working Capital
-1.22-0.39-1.171.480.13
SEC Filings: 10-K · 10-Q